FDA gives final approval to Depo amid concerns over safety, cost and coercion.
D000569:Americas; D001943:Breast Neoplasms; D003267:Contraception; D003268:Contraception Behavior; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D019049:Developed Countries; D003906:Developing Countries; D004194:Disease; D004467:Economics; D016889:Endometrial Neoplasms; D005193:Family Planning Services; D006077:Government Agencies; D007390:International Agencies; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms; D009656:North America; D009938:Organizations; D010051:Ovarian Neoplasms; D010060:Ovulation; D011203:Poverty; D012923:Social Class; D012959:Socioeconomic Factors; D014480:United Nations; D014481:United States; D014492:United States Public Health Service; D002583:Uterine Cervical Neoplasms; D014944:World Health Organization
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate
Americas; Breast Cancer; Cancer; Cervical Cancer; Contraception; Contraception Failure; Contraceptive Agents, Female--contraindications; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--contraindications; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--contraindications; Contraceptive Agents--side effects; Contraceptive Mode Of Action; Contraceptive Usage; Depo-provera--contraindications; Depo-provera--side effects; Developed Countries; Developing Countries; Diseases; Economic Factors; Endometrial Cancer; Family Planning; Government Agencies; International Agencies; Low Income Population--women; Medroxyprogesterone Acetate--contraindications; Medroxyprogesterone Acetate--side effects; Neoplasms; North America; Northern America; Organizations; Ovarian Cancer; Ovulation Suppression; Reversibility; Social Class; Socioeconomic Factors; Socioeconomic Status; Un; United States; Usaid; Usphs; Who